Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Varenicline tartrate tablets (Changpei) (maintenance pack)

Suitable for adults to quit smoking. See the instructions for details. More role
App download minus 10 yuan
Common name:
Varenicline Tartrate Tablets
Product No.:
C14202015046
Approval No.:
H20171222 (original registration certificate No.: h20150040) (inquired by the State Drug Administration)
Jianke price:
¥354.00
Product specification:
1.0mg*28s 0.5mg*11s+1mg*14s 0.5mg * 11S + 1mg * 14s * 1 box + 1.0mg * 28s * 5 boxes (0.5mg * 11S + 1mg * 14s) + 1.0mg * 28s * 2 boxes
Manufacturer:
R-Pharm Germany GmbH

Warm tips, this product is out of stock now(you can book the product first,already existing0Person reservation

    Jianke promises:
    Genuine guarantee
    Bank remittance / transfer online payment
    • Product introduction
    • instructions
    • Qualification certificate
    • Relevant information
    Product name Varenicline tartrate tablets (Changpei) (maintenance pack)
    Main raw materials The main ingredient of this product is vanillin tartrate.
    Main role Suitable for adults to quit smoking. See the instructions for details.
    Product specification 1.0mg*28s
    Usage and dosage This product is used for oral administration. First, increase the dose for one week according to the following method, and then the recommended dose is 1mg twice a day. 1. Day 1-3: 0.5mg, once a day (white tablets) 2. Day 4-7: 0.5mg, twice a day (white tablets) 3. Day 8 - end of treatment: 1mg, twice a day (light blue tablets) 4. The patient should set a smoking cessation date and start taking this product 1-2 weeks before this date. 5. For patients who cannot tolerate the adverse reactions of this product, the dose can be temporarily or permanently reduced to 0.5mg twice a day. 6. This product should be swallowed in whole with water. It can be taken before and after meals. 7. The patient should take this product for 12 weeks. 8. For patients who have successfully quit smoking after 12 weeks of treatment, consider adding a 12 week course of treatment, and the dose is still 1mg twice a day (see the inner packaging instructions for details)
    manufacturing enterprise R-Pharm Germany GmbH
    Jianke commitment
    • Genuine guarantee, formal invoice

      Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

    • Private packaging, privacy protection

      When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

    • Efficient logistics and safe arrival

      All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

    • Three warehouses to ensure inventory

      Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

    [drug name] Varenicline tartrate tablets (Changpei) (maintenance pack)

    [common name] Varenicline Tartrate Tablets

    [specification and model] 1.0mg*28s

    [manufacturer] R-Pharm Germany GmbH

    [drug type] Western medicine

    [approval No.] H20171222 (original registration certificate No.: h20150040)

    [validity period] 24 months

    [functional indications] Suitable for adults to quit smoking. See the instructions for details.

    [usage and dosage] This product is used for oral administration. First, increase the dose for one week according to the following method, and then the recommended dose is 1mg twice a day. 1. Day 1-3: 0.5mg, once a day (white tablets) 2. Day 4-7: 0.5mg, twice a day (white tablets) 3. Day 8 - end of treatment: 1mg, twice a day (light blue tablets) 4. The patient should set a smoking cessation date and start taking this product 1-2 weeks before this date. 5. For patients who cannot tolerate the adverse reactions of this product, the dose can be temporarily or permanently reduced to 0.5mg twice a day. 6. This product should be swallowed in whole with water. It can be taken before and after meals. 7. The patient should take this product for 12 weeks. 8. For patients who have successfully quit smoking after 12 weeks of treatment, consider adding a 12 week course of treatment, and the dose is still 1mg twice a day (see the inner packaging instructions for details)

    [adverse reactions] 1. Whether or not receiving smoking cessation treatment, smoking cessation itself is accompanied by a variety of symptoms. For example, it has been reported that patients trying to quit smoking have irritability, depression, insomnia, irritability, frustration, anger, anxiety, inability to concentrate, restlessness, decreased heart rate, increased appetite or weight gain. The design and result analysis of the clinical study of this product did not distinguish the correlation between the adverse events and drug or nicotine withdrawal. 2. Many clinical studies of this product involve about 4000 patients, and the longest treatment time is 1 year (average administration of 84 days). If adverse reactions occur, they usually occur in the first week of treatment, and the severity is mostly mild to moderate. There was no difference in the incidence of adverse reactions among different age, race or gender. 3. After completing the initial dose increase, the patient took the recommended dose twice a day, 1mg each time. The most reported adverse event was nausea (28.6%). Nausea mostly occurs in the early stage of treatment, the severity is mild to moderate, and rarely leads to the interruption of treatment. 4. The proportion of patients who interrupted treatment due to adverse events was 11.4% in the treatment group and 9.7% in the placebo group. Among these patients, the treatment interruption rates of common adverse events in the treatment group were nausea (2.7%, 0.6% in the placebo group), headache (0.6%, 1.0% in the placebo group), insomnia (1.3%, 1.2% in the placebo group), and abnormal dreams (0.2%, 0.2% in the placebo group). 5. The following table lists the adverse reactions with higher incidence in the treatment group than that in the placebo group, which are arranged according to the type and frequency of system organs (see the inner packaging instructions for details).

    [precautions] 1. With the advice and support of others, patients who are willing to quit smoking are more likely to succeed in smoking cessation treatment. 2. Patients with renal impairment 1) Patients with mild (estimated creatinine clearance > 50ml / min and ≤ 80ml / min) to moderate (estimated creatinine clearance ≥ 30ml / min and ≤ 50ml / min) renal impairment do not need to adjust the dose. 2) For patients with moderate renal impairment and unable to tolerate adverse events, the dose can be reduced to 1mg once a day. 3) For patients with severe renal function injury (estimated creatinine clearance rate < 30ml / min), the recommended dose is 1mg once a day. The dosage should start from 0.5mg once a day and increase to 1mg once a day after 3 days. The clinical experience of patients with end-stage renal disease is preferred. Therefore, it is not recommended to use this product in this population (see the inner package manual for details). Please read the manual carefully and follow the doctor's advice.

    [taboo] Allergic to the active ingredient or any auxiliary ingredient of this product.

    [listing Permit Holder] R-PharmGermanyGmbH

    [packaging unit] box

    [main ingredients] The main ingredient of this product is vanillin tartrate.

    [character] Light blue film coated tablets.

    [applicable population] adult

    [medication for pregnant and lactating women] pregnant woman Data on the use of this product in pregnant women are limited. Animal studies show that this product has reproductive toxicity (see [pharmacology and toxicology]). The potential risks of human applications are unknown. This product should not be used during pregnancy. lactation It is not clear whether varenicline is secreted in human milk. Animal studies suggest that vancomyl can be secreted into milk. The benefits of breastfeeding for infants and the benefits of this product treatment for breastfeeding women should be weighed to make a decision to continue or terminate breastfeeding or continue or terminate this product treatment. birth There is no clinical data on the effect of this product on fertility. The results of male and female fertility studies in rats suggest that this product may be harmless to human fertility (see [pharmacology and toxicology]).

    [medication for children] Due to the limited data on the safety and efficacy of this product in children or adolescents under the age of 18, it is not recommended to apply this product to this population. See usage and dosage.

    [medication for elderly patients] Because elderly patients are more prone to renal dysfunction, prescription doctors should consider the renal function of elderly patients. See usage and dosage.

    [storage] Sealed, stored below 25 ℃

    Praise degree

    zero%

      reminder

      Dear customer:

      In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

      Varenicline tartrate tablets (Changpei) (maintenance pack)

      ¥354.00

      reminder

      To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

      Please enter the correct verification code!
      Loding...
      Can't see clearly. Change one

      Dear customer:

      Your callback failed this time. Please re-enter the verification code to try. Thank you!